DECEMBER - JANUARYLIFE SCIENCES REVIEW6The market for pharmaceutical CDMOs in Europe reached $37.17 billion in 2019 and is expected to increase by 6.7% annually from 2020 to 2030 as a result of rising demand for specialty drugs and biological therapies, increased pressure to keep drug development costs under control, and rising healthcare costs.In their capacity as adaptable third-party service providers, CDMOs assist pharmaceutical businesses throughout the whole process of producing medications, including the research and development phases as well as the manufacturing, formulation, and finishing phases. With a more dynamic mergers and acquisitions (M&A) landscape brought on by consolidation, CDMOs have grown during the past ten years.In the past, CDMOs operated under a business model that mostly concentrated on serving as outside contractors for the production of established pharmaceuticals. This concept includes the expansion of capacity through the purchase of pharmaceutical businesses' manufacturing facilities. However, CDMOs are increasingly taking the lead in innovation, encompassing more aspects of the pharmaceutical industry than just manufacturing, and generating new sources of income. CDMOs can quickly increase their capabilities through acquisitions, enabling them to offer technically sophisticated services at scale.In this edition of Life Sciences Review, we present the list of top CDMOs in Europe. Curtis Health Caps and Idorsia Pharmaceutical Ltd., are some of the prominent CDMOs in the region. We also bring to you thought leadership articles and exclusive insights from expert CIOs and CXOs--Stefan Abele, Senior Vice President, Head of Chemical Development and Commercial Manufacturing, Idorsia Pharmaceutical ltd., Brian D. Fry, Senior Director, Cell Therapy CDMO, Charles River Laboratories, Dr. Sarah Tregenza, Ph.D., BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre Group presenting their views and opinions on how organizations can incorporate changes. We hope the valuable insights from industry thought leaders and the CDMOs featured in this edition help you make informed decisions for your organization. Let us know your thoughts!EDITORIALThe Next Wave of Pharmaceutical CDMOsCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com December - January, Vol 03, Issue - 06 Published by ValleyMedia, Inc. (ISSN 2831-8331)To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersGiftson JoshuaJoe Philip Shirley FaithRussell ThomasVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsVictor Cruz
< Page 5 | Page 7 >